Drug target Mendelian randomisation (MR) analyses conducted in European populations, leveraging genomic variants within and around the CETP locus, have consistently indicated that sufficiently potent on-target inhibition of CETP is anticipated to decrease CHD risk5–7. Here, CETP is linked to coronary artery disorder.